Fracture: The Paper Anniversary

Last summer, almost to the day, I fractured and dislocated my knee. Let’s just say it wasn’t pleasant. I was playing (soccer/football) and the tackle was “reckless and ridiculous.” Here’s my post from a year ago. So, on the anniversary of the tackle and an injury that sent my life in new directions, here areContinue reading “Fracture: The Paper Anniversary”

Big Pharma Round-Up II

Here is a snapshot of the past week in Big Pharma news.  This is coming at you a little early because of the Christmas slowdown. Happy holidays. To kick off: The drug industry spent big! Threats to high drug prices prompted biggest lobbying/PR/advertising/influence-buying surge by trade group PhRMA in nearly a decade. We got theirContinue reading “Big Pharma Round-Up II”

Harnessing the Fierce Energy of Counterculture

Mental health knowledge and practice was highly contested in the 1960s and 70s. Struggles over homosexuality and radicalism, drug use and replicable drug trials, were part of a unique countercultural moment. These were wild times. Transactional analysis, developed by Eric Berne and Claude Steiner, was also part of this fiercely energetic moment. In January 2017Continue reading “Harnessing the Fierce Energy of Counterculture”

UK Drugs Strategy – July 2017 – Same old, same old?

This past week the UK Government released a Drugs Strategy. Here is some of the reaction to the document, which is available here. Media Roundup. * From The Independent:   The Government’s latest policy relaunch aimed at tackling illegal drugs amid soaring death rates has been heavily criticised by campaigners who say it fails toContinue reading “UK Drugs Strategy – July 2017 – Same old, same old?”

Donald Trump’s FDA and the ‘United States of Oxy’

How will the pharmaceutical industry be impacted under the Trump administration? Who’s the new FDA Commissioner? How will e-cigarettes be effected? How will the opioid crisis be impacted? Trump’s FDA and “the United States of Oxy” By Lucas Richert The US Food and Drug Administration (FDA) may be headed for a major overhaul under theContinue reading “Donald Trump’s FDA and the ‘United States of Oxy’”

CFP. Mental Health and Money: Past and Present

A Call for Papers. Socioeconomic factors and mental health: past and present Editors: Professor Matthew Smith and Dr Lucas Richert (University of Strathclyde, UK) This article collection will examine how the relationship between socioeconomic factors and mental health has been and is understood in an array of different places and periods. Although much of theContinue reading “CFP. Mental Health and Money: Past and Present”

Beyond Vape Fear

Richard Roope, of the RCGP, has recently released a report on e-cigarettes. Essentially, the Royal College of General Practitioners, the official channel for General Practice of Medicine in the UK, has given their informed recommendations to health professionals regarding smoking cessation and the use of e-cigarette. The recommendations: 1. GPs provide advice on the relative risksContinue reading “Beyond Vape Fear”

EpiPen Price Gouging is Old News

On Thursday, Mylan announced a series of steps that will make its EpiPen more affordable for some patients. Over the past few years, Mylan had raised a standard two-pack of EpiPens to roughly $600. It had cost $100 in 2009. Then, following a recent uproar, including a public tongue-lashing from Hillary Clinton and a US SenatorContinue reading “EpiPen Price Gouging is Old News”

Medical History on the Move

I have a new blog post on the University of Toronto’s site.   I’m incredibly excited to be working with CBMH/BCHM and University of Toronto Press over the summer months. It will be my pleasure to help out with journal’s migration to the UofT’s publishing platform. As part of this transition, we are moving allContinue reading “Medical History on the Move”